Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Candidiasis Drugs Market size was over USD 872.46 million in 2024 and is poised to exceed USD 1.88 billion by 2037, growing at over 6.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of candidiasis drugs is evaluated at USD 917.7 million.
Candida is a yeast, that causes infection in the mucosal layer. The growth of the market can be attributed to the growing cases of yeast infection across the world, backed by poor immunity, sanitation practices, and others. The increasing health awareness, availability of anti-fungal drugs, and growing investment in development of new drugs, is estimated to boost the market growth. Candida is usually present inside the skin, in parts lined with mucous, such as the mouth, throat, gut, and vagina, without causing any problems. Infections are caused when the yeast grows out of control, due to high amount of sugar in blood, high humidity, or poor hygiene. Diabetes is a major factor for candidiasis infection, as raised blood sugar promotes yeast activation. The growing incidences of diabetes is estimated to boost the market growth over the forecast period. According to the report by the World Health Organization (WHO), 422 million people worldwide suffer from diabetes, in countries of all income levels, and around 1.6 million deaths are directly attributed to it each year.
Candidiasis Drugs Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Candidiasis
- Rising R&D Activities for Drug Development
- Easy Availability of Anti-fungal Drugs
Challenges
- Lack of Health Awareness amongst People
- Absence of Proper Healthcare Infrastructure
Candidiasis Drugs Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.1% |
|
Base Year Market Size (2024) |
USD 872.46 million |
|
Forecast Year Market Size (2037) |
USD 1.88 billion |
|
Regional Scope |
|
Candidiasis Drugs Segmentation
The market is segmented by disease type into oral, vaginal, cutaneous, invasive, and others, out of which, the vaginal segment is anticipated to hold the notable share in the global candidiasis drugs market over the forecast period on the back of the increasing cases of vaginal candidiasis, backed by lack of sexual health awareness and hygiene amongst individuals, especially in the middle and low-income countries. According to the data by the Center for Disease Control and Prevention (CDC), about 20% women who have candida in the vagina, do not notice any symptoms.
Vaginal candidiasis is not a sexually transmitted disease. It is caused due to poor hygiene, hot and humid environment around the vulva, sharing toilets, and even due to drinking less amount of water. Mild infections are often overlooked, due to the embarrassment and taboo associated with diseases in the private parts, resulting in severe infection and even hospitalization. This is a major factor expected to drive the segment growth. Pregnancy and hormonal contraceptives are also a major cause of candidiasis in the vagina.
Our in-depth analysis of the global candidiasis drug market includes the following segments:
|
By Disease Type |
|
|
By Drug Type |
|
|
By End-User
|
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportCandidiasis Drugs Industry - Regional Synopsis
On the basis of geographical analysis, the global candidiasis drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is predicted to dominate majority revenue share by 2037, driven by climatic conditions that promote yeast infection. Moreover, lack of proper sanitation in the region, and lower rate of health awareness, especially in rural parts of the developing countries, is estimated to boost the regional market growth. The market in the Middle East and Africa region is also estimated to witness significant growth owing to the lack of hygiene and sanitation, and hot & humid climate of the region.
The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the constantly rising cases of candidiasis, especially invasive candidiasis in the region. As per a report by the CDC, approximately 25,000 cases of candidemia are recorded in the United States each year. The high prevalence of diabetes is one of the primary factors for the increasing candidiasis cases in the region.
Companies Dominating the Candidiasis Drugs Landscape
- Biogen, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Glenmark Pharmaceuticals
- Merck KGaA
- Novartis AG
- Sanofi-aventis Groupe
- Teva Pharmaceutical Industries Ltd.
- Boehringer Ingelheim International GmbH
- Daiichi Sankyo Company, Limited
- Siemens Healthcare GmbH
In the News
- June, 2021: Novartis AG announced its collaboration with Hewlett Packard Enterprise to expand its distribution globally.
- August, 2017: Sanofi-aventis and Bristol-Myers Squibb Company announced FDA approval for the antiplatelet agent PLAVIX.
Author Credits: Radhika Pawar
- Report ID: 3650
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
